144 results on '"Hessmann E"'
Search Results
2. MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies
3. Epigenetische Strategien in der Krebstherapie
4. NFATc1 as a therapeutic target in FLT3-ITD-positive AML
5. Identifying Specificity Protein 2 as a key marker for diabetic encephalopathy in the context of predictive, preventive, and personalized medicine
6. Effect of tumor microenvironment in pancreatic cancer on the loss of β-cell mass: implications for type 3c diabetes
7. Epigenetische Therapien in der Krebsbehandlung: Chancen und Herausforderungen
8. Prognostic biomarker MICAL2 and associates with proliferation, migration and immune infiltration in pancreatic adenocarcinoma
9. Combination of S-1 and the oral ATR inhibitor ceralasertib is effective against pancreatic cancer cells
10. A shorter splicing isoform antagonizes ZBP1 to modulate cell death and inflammatory responses
11. Machine Learning Developed a MYC Expression Feature-Based Signature for Predicting Prognosis and Chemoresistance in Pancreatic Adenocarcinoma
12. Harnessing Plant Flavonoids to Fight Pancreatic Cancer
13. Osteogenesis imperfecta type 10 and the cellular scaffolds underlying common immunological diseases
14. Advances in A-to-I RNA editing in cancer
15. Systemic tumor regression with synergy therapy: radiotherapy and CAR-T
16. Writers, readers, and erasers RNA modifications and drug resistance in cancer
17. Unbiased discovery of cancer pathways and therapeutics using Pathway Ensemble Tool and Benchmark
18. Concomitant targeting of FLT3 and SPHK1 exerts synergistic cytotoxicity in FLT3-ITD+ acute myeloid leukemia by inhibiting β-catenin activity via the PP2A-GSK3β axis
19. ADAR1 prevents ZBP1-dependent PANoptosis via A-to-I RNA editing in developmental sevoflurane neurotoxicity
20. The cross-talk between the macro and micro-environment in precursor lesions of pancreatic cancer leads to new and promising circulating biomarkers
21. Targeted delivery of CEBPA-saRNA for the treatment of pancreatic ductal adenocarcinoma by transferrin receptor aptamer decorated tetrahedral framework nucleic acid
22. Combining single-cell and bulk RNA sequencing, NK cell marker genes reveal a prognostic and immune status in pancreatic ductal adenocarcinoma
23. Injectable hybrid hydrogels enable enhanced combination chemotherapy and roused anti-tumor immunity in the synergistic treatment of pancreatic ductal adenocarcinoma
24. Polycomb repressive complex 2 and its core component EZH2: potential targeted therapeutic strategies for head and neck squamous cell carcinoma
25. Deubiquitinase PSMD7 facilitates pancreatic cancer progression through activating Nocth1 pathway via modifying SOX2 degradation
26. Pancreatic cancer acquires resistance to MAPK pathway inhibition by clonal expansion and adaptive DNA hypermethylation
27. Macrophages reprogramming driven by cancer-associated fibroblasts under FOLFIRINOX treatment correlates with shorter survival in pancreatic cancer
28. Cellular zinc metabolism and zinc signaling: from biological functions to diseases and therapeutic targets
29. Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept
30. ZBP1 causes inflammation by inducing RIPK3-mediated necroptosis and RIPK1 kinase activity-independent apoptosis
31. Combination therapy involving HSP90 inhibitors for combating cancer: an overview of clinical and preclinical progress
32. Targeting the pancreatic tumor microenvironment by plant-derived products and their nanoformulations
33. Regulation of Zbp1 by miR-99b-5p in microglia controls the development of schizophrenia-like symptoms in mice
34. From complexity to clarity: unravelling tumor heterogeneity through the lens of tumor microenvironment for innovative cancer therapy
35. Cancer cell plasticity, stem cell factors, and therapy resistance: how are they linked?
36. Ferroptosis: potential targets and emerging roles in pancreatic diseases
37. Combined analytical approach empowers precise spectroscopic interpretation of subcellular components of pancreatic cancer cells
38. Epigenetic control of pancreatic cancer metastasis
39. Integrative multiomics and weighted network approach reveals the prognostic role of RPS7 in lung squamous cell carcinoma pathogenesis
40. USP7-mediated JUND suppresses RCAN2 transcription and elevates NFATC1 to enhance stem cell property in colorectal cancer
41. Glial cell-derived soluble factors increase the metastatic potential of pancreatic adenocarcinoma cells and induce epithelial-to-mesenchymal transition
42. LncRNA BCAN-AS1 stabilizes c-Myc via N6-methyladenosine-mediated binding with SNIP1 to promote pancreatic cancer
43. Self-assembled lipid–prodrug nanoparticles
44. Crosstalk of ferroptosis regulators and tumor immunity in pancreatic adenocarcinoma: novel perspective to mRNA vaccines and personalized immunotherapy
45. Chromatin accessibility uncovers KRAS-driven FOSL2 promoting pancreatic ductal adenocarcinoma progression through up-regulation of CCL28
46. The added value of [68Ga]Ga-DOTA-FAPI-04 PET/CT in pancreatic cancer: a comparison to [18F]F-FDG
47. Epigenetic priming targets tumor heterogeneity to shift transcriptomic phenotype of pancreatic ductal adenocarcinoma towards a Vitamin D susceptible state
48. Mechanisms of PANoptosis and relevant small-molecule compounds for fighting diseases
49. SNHG17 alters anaerobic glycolysis by resetting phosphorylation modification of PGK1 to foster pro-tumor macrophage formation in pancreatic ductal adenocarcinoma
50. A super-enhancer-regulated RNA-binding protein cascade drives pancreatic cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.